000			03187nam a22003017a 4500
999			_c12291 _d12291
001			MED 2021 0002
003			PILC
005			20240720153244.0
008			220428b xxu||||| |||| 00| 0 eng d
040			_beng _cFEU-NRMF MEDICAL LIBRARY _erda
041			_aenglish
050			_aMED 2021 0002
245			_aApplicability of CALL score as a predictor of risk progression in patients with COVID-19 pneumonia / _cHeliza Marie S. Nagano.
260			_aFairview, Quezon City; _bDepartment of Internal Medicine, FEU-NRMF, _c2021.
300			_a22 pages: _billustrations, tables; _c(in folder) + _ewith flash drive (soft copy).
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes bibliographical references.
520			_aAbstract: COVID-19 did affect the healthcare system in terms of its resources and capabilities. Early intervention is needed to effectively manage patients for the possibility of disease progression. This study aims to validate the CALL Score in predicting the risk progression of patient with COVID-19 pneumonia at Far Eastern University Nicanor Reyes Medical Center. Chart review was done to retrieve data of admitted patient with COVID-19 from March 2020 to February 2021. Medical charts of patients aged 18 years old and above with RT-PCR confirmed infection were included through a purposive sampling strategy. All patients were classified as low, moderate, or high risk based on their total score. Patients were grouped into two based on the disease progression (stable or progressive). Extended Chi-square or Fisher's Exact Test were used to determine significant association of the four CALL score parameters between the stable and progressive groups. The area under the ROC (AUROC) and optimal cutoff values were determined and assessed by the sensitivity, specificity, predictive values and likelihood ratios. Overall, 143 patients were divided into a stable group (n=109) and a progressive group (n=34). Generally, presence of comorbidities (p=0.001), age (p=0.0005), lymphocyte count (p<0.0001), and LDH levels (p<0.0001) were significantly different between the stable and progressive group. Using a cutoff of 6 points, the positive-predictive value (95% CI) was 30.3% (21.8=39.8%) and the negative-predictive value (95% CI) was 97.1% (84.7-99.9%) with an AUC of 0.637 (0.585, 0.697). Using a cutoff of 9 points, the positive-predictive value (95% CI) was 43.1% (30.8-56.0%) and the negative-predictive value (95% CI) was 92.3% (84.0-97.1%) with an AUC of 0.742 (0.663-0.821). AUCs of two cutoff points were found to have significant difference (p=0.0062). We found significant differences in terms of the demographic characteristics, laboratory parameters, and clinical history of stable and progressive patients based on their total CALL score. Thus, utility CALL score in the local setting might be considered for early management of COVID-19 pneumonia.
521			_aRESDM
650			_aCOVID-19
650			_aprogression
650			_avalidation
650			_aCALL Score
700			_aNagano, Heliza Marie S., MD. _eprincipal investigator
942			_2lcc _cRU